Bristol-Myers Squibb Co. (BMS), of New York, and Samsung Biologics, of Seoul, South Korea, said they will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several BMS biologic medicines at its Incheon manufacturing site.